Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 8:16:1565345.
doi: 10.3389/fphar.2025.1565345. eCollection 2025.

Efficacy of Kangfuxin liquid for preventing and treating chemotherapy-induced oral mucositis: a systematic review and meta-analysis of randomized controlled trials

Wei Sun  1 , Yang Jian  2 , Xiaolin Feng  1 , Minru Zhao  2 , Yuan Liu  1
Affiliations

Efficacy of Kangfuxin liquid for preventing and treating chemotherapy-induced oral mucositis: a systematic review and meta-analysis of randomized controlled trials

Wei Sun et al. Front Pharmacol. .

Abstract

Objective: Chemotherapy-induced oral mucositis (CTOM) is a common side effect affecting 20%-40% of cancer patients receiving chemotherapy. Kangfuxin liquid (KFXL) has been used clinically to prevent and treat CTOM, but the evidence has not been systematically evaluated. This study aimed to evaluate the preventive and therapeutic effects of KFXL on CTOM.

Methods: Nine electronic databases were searched to identify KFXL-related randomized controlled trials (RCTs) for the prevention and treatment of CTOM from inception to September 2024. The primary outcomes were incidence rate, efficacy rate and cure rate, and the secondary outcomes was healing time.

Results: Twenty-one trials involving 1825 patients were included in this review. The results of our meta-analysis showed that, compared with basic oral care (BOC), KFXL significantly reduced the incidence rate of CTOM and severe CTOM (RR = 0.54, p < 0.00001; RR = 0.23, p < 0.00001, respectively), improved the efficacy rate of CTOM and severe CTOM (RR = 1.23, p = 0.0003; RR = 1.99, p = 0.05, respectively), improved the cure rate of CTOM (RR = 2.06, p = 0.0004),and accelerated the healing process (MD = -2.48, p < 0.00001). However, KFXL and other drugs have the same efficacy rate in treating CTOM and severe CTOM (RR = 1.00, p = 0.99; RR = 1.00, p = 1.00, respectively), and the same cure rate in CTOM (RR = 0.91, p = 0.39), and the same healing time (MD = -0.01, p = 1.00).

Conclusion: The results suggest that KFXL may provide more benefit in the prevention and treatment for CTOM compared to BOC. Although KFXL may be a promising drug for the prevention and treatment of CTOM, the evidence is insufficient to prove its superiority over other guideline-recommended treatment.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585859, ID: CRD42024585859.

Keywords: Kangfuxin Liquid; chemotherapy; meta-analysis; oral mucositis; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study selection process.
FIGURE 2
FIGURE 2
Risk of bias graph.
FIGURE 3
FIGURE 3
Risk of bias summary.
FIGURE 4
FIGURE 4
Forest plot of preventive effect of KFXL on CTOM compared with BOC. KFXL: Kangfuxin Liquid; BOC: basic oral care; M-H: Mantel-Haenszel.
FIGURE 5
FIGURE 5
Forest plot of preventive effect of KFXL on severe CTOM compared with BOC. KFXL: Kangfuxin Liquid; BOC: basic oral care; M-H: Mantel-Haenszel.
FIGURE 6
FIGURE 6
Forest plot of KFXL on efficacy rate on CTOM compared with BOC and other medicines. KFXL: Kangfuxin Liquid; BOC: basic oral care; M-H: Mantel-Haenszel.
FIGURE 7
FIGURE 7
Forest plot of KFXL on efficacy rate on severe CTOM compared with BOC and other medicines. KFXL: Kangfuxin Liquid; BOC: basic oral care; M-H: Mantel-Haenszel.
FIGURE 8
FIGURE 8
Forest plot of KFXL on cure rate on CTOM compared with BOC and other medicines. KFXL: Kangfuxin Liquid; BOC: basic oral care; M-H: Mantel-Haenszel.
FIGURE 9
FIGURE 9
Forest plot of KFXL on healing time on CTOM compared with BOC and other medicines. KFXL: Kangfuxin Liquid; BOC: basic oral care; I-V: Inverse Variance.
See this image and copyright information in PMC

References

    1. Ali S. M., Siddiqui R., Ong S. K., Shah M. R., Anwar A., Heard P. J., et al. (2017). Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). Appl. Microbiol. Biotechnol. 101 (1), 253–286. 10.1007/s00253-016-7872-2 - DOI - PubMed
    1. Alsulami F. J., Shaheed S. U. (2022). Oral cryotherapy for management of chemotherapy-induced oral mucositis in haematopoietic cell transplantation: a systematic review. BMC cancer 22 (1), 442. 10.1186/s12885-022-09539-8 - DOI - PMC - PubMed
    1. Ao M., Liu Y. F. (2013). Clinical observation of Kangfuxin Liquid in the treatment of stomatitis caused by chemotherapy in children with acute lymphoblastic leukemia. J. West Chin. Med. 28 (8), 1245–1246. 10.7507/1002-0179.20130388 - DOI
    1. Bao L. C. (2013). Observation on the effect of Kangfuxin Liquid in preventing stomatitis caused by postoperative chemotherapy for breast cancer. J. Zhejiang Clin. Med. 15 (12), 1880–1881.
    1. Bertolini M., Ranjan A., Thompson A., Diaz P. I., Sobue T., Maas K., et al. (2019). Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection. PLoS Pathog. 15 (4), e1007717. 10.1371/journal.ppat.1007717 - DOI - PMC - PubMed

Publication types

LinkOut - more resources